中国全科医学 ›› 2022, Vol. 25 ›› Issue (05): 625-630.DOI: 10.12114/j.issn.1007-9572.2021.01.034
所属专题: 心力衰竭最新文章合集; 心血管最新文章合集; 安全用药最新文章合集; 精神卫生最新文章合集
杨荣军, 史钰芳, 王庆海*
收稿日期:
2021-06-15
修回日期:
2021-09-25
出版日期:
2022-02-15
发布日期:
2022-01-29
通讯作者:
王庆海
基金资助:
Advances in Mechanism of Coexistence and Pharmaceutical Treatment of Chronic Heart Failure and Depression
YANG Rongjun,SHI Yufang,WANG Qinghai*
Cardiovascular Department,the Second People's Hospital of China Three Gorges University,Yichang 443000,China
*Corresponding author:WANG Qinghai,Chief physician;E-mail:285858961@qq.com
Received:
2021-06-15
Revised:
2021-09-25
Published:
2022-02-15
Online:
2022-01-29
摘要: 慢性心力衰竭(CHF)和抑郁症的共病率为10%~79%,二者的发病机制均涉及免疫炎症系统激活、胰岛素抵抗、肠道菌群失调等方面,而其机制的调节亦是双向的、复杂的。现有的诊疗指南及临床实践中尚缺乏对二者同时有效的药物,但有近期报道部分药物如沙库巴曲缬沙坦、新型抗抑郁药、参松养心胶囊和芪苈强心胶囊、肠道菌群调节剂等对二者均有一定的治疗作用。本文将对二者的共同发病机制及药物治疗的研究进展进行综述,为CHF和抑郁症共病的临床诊断及治疗提供新的思路和依据。
中图分类号:
YANG Rongjun, SHI Yufang, WANG Qinghai.
Advances in Mechanism of Coexistence and Pharmaceutical Treatment of Chronic Heart Failure and Depression [J]. Chinese General Practice, 2022, 25(05): 625-630.
[1] | MA L Y, CHEN W W, GAO R L,et al. China cardiovascular diseases report 2018: an updated summary[J]. J Geriatr Cardiol,2020,17(1):1-8. DOI:10.11909/j.issn.1671-5411.2020.01.001. |
[2] | SOKORELI I, DE VRIES J J G, PAUWS S C,et al. Depression and anxiety as predictors of mortality among heart failure patients:systematic review and meta-analysis[J]. Heart Fail Rev,2016,21(1):49-63. DOI:10.1007/s10741-015-9517-4. |
[3] | RUSTAD J K, STERN T A, HEBERT K A,et al. Diagnosis and treatment of depression in patients with congestive heart failure:a review of the literature[J]. Prim Care Companion CNS Disord,2013,15(4):PCC.13r01511. DOI:10.4088/PCC.13r01511. |
[4] | CELIK E, CAY S, SENSOY B,et al. Heart failure functional class associated with depression severity but not anxiety severity[J]. Acta Cardiol Sin,2016,32(1):55-61. |
[5] | YU H W, DONG Y Y, DANG Y H. The modulatory activity of T cell immunoglobulin and mucin domain-containing protein 3 on T lymphocytes in patients with chronic heart failure[J]. Zhonghua Yi Xue Za Zhi,2020,100(17):1315-1319. DOI:10.3760/cma.j.cn112137-20190823-01876. |
[6] | SEGIET O A, PIECUCH A, MIELANCZYK L,et al. Role of interleukins in heart failure with reduced ejection fraction[J]. Anatol J Cardiol,2019,22(6):287-299. DOI:10.14744/AnatolJCardiol.2019.32748. |
[7] | KOWALCZYK M, SZEMRAJ J, BLIZNIEWSKA K,et al. An immune gate of depression - Early neuroimmune development in the formation of the underlying depressive disorder[J]. Pharmacol Rep,2019,71(6):1299-1307. DOI:10.1016/j.pharep.2019.05.022. |
[8] | DICKENS C. Depression in people with coronary heart disease:prognostic significance and mechanisms[J]. Curr Cardiol Rep,2015,17(10):1-10. DOI:10.1007/s11886-015-0640-6. |
[9] | MAO R Z, ZHANG C, CHEN J,et al. Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression[J]. J Affect Disord,2018,237(9):65-72. |
[10] | MILLER A H, RAISON C L. The role of inflammation in depression:from evolutionary imperative to modern treatment target[J]. Nat Rev Immunol,2016,16(1):22-34. |
[11] | SU J, WANG J H, MA Y Y,et al. Inflammation associated with chronic heart failure leads to enhanced susceptibility to depression[J]. FEBS J,2019,286(14):2769-2786. DOI:10.1111/febs.14839. |
[12] | ZHANG H F, ZHANG X, GAO F. Insulin and cardiovascular protection:from bench to bedside[J]. Acta Physiol Sin,2018,70(1):61-70. |
[13] | ZHENG L L, LI B B, LIN S H,et al. Role and mechanism of cardiac insulin resistance in occurrence of heart failure caused by myocardial hypertrophy[J]. Aging (Albany NY),2019,11(16):6584-6590. DOI:10.18632/aging.102212. |
[14] | HAMER J A, TESTANI D, MANSUR R B,et al. Brain insulin resistance:a treatment target for cognitive impairment and anhedonia in depression[J]. Exp Neurol,2019,315:1-8. |
[15] | ZOU X H, SUN L H, YANG W,et al. Potential role of insulin on the pathogenesis of depression[J]. Cell Prolif,2020,53(5):E12806-12819. DOI:10.1111/cpr.12806. |
[16] | SOTO M, HERZOG C, PACHECO J A,et al. Gut microbiota modulate neurobehavior through changes in brain insulin sensitivity and metabolism[J]. Mol Psychiatry,2018,23(12):2287-2301. DOI:10.1038/s41380-018-0086-5. |
[17] | JIA Q J, LI H, ZHOU H,et al. Role and effective therapeutic target of gut microbiota in heart failure[J]. Cardiovasc Ther,2019,2019(11):5164298-5164309. |
[18] | CHEN X, LI H Y, HU X M,et al. Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure[J]. Chin Med J (Engl),2019,132(15):1843-1855. DOI:10.1097/CM9.0000000000000330. |
[19] | SATA Y, MARQUES F Z, KAYE D M. The emerging role of gut dysbiosis in cardio-metabolic risk factors for heart failure[J]. Curr Hypertens Rep,2020,22(5):38-46. DOI:10.1007/s11906-020-01046-0. |
[20] | LIU R T, WALSH R F L, SHEEHAN A E. Prebiotics and probiotics for depression and anxiety:a systematic review and meta-analysis of controlled clinical trials[J]. Neurosci Biobehav Rev,2019,102:13-23. DOI:10.1016/j.neubiorev.2019.03.023. |
[21] | LIANG S, WU X L, HU X,et al. Recognizing depression from the Microbiota-Gut-Brain axis[J]. Int J Mol Sci,2018,19(6):E1592. DOI:10.3390/ijms19061592. |
[22] | AMADIO P, ZARÀ M, SANDRINI L,et al. Depression and cardiovascular disease:the viewpoint of platelets[J]. Int J Mol Sci,2020,21(20):E7560. DOI:10.3390/ijms21207560. |
[23] | WILLIAMS M S, ZIEGELSTEIN R C, MCCANN U D,et al. Platelet serotonin signaling in patients with cardiovascular disease and comorbid depression[J]. Psychosom Med,2019,81(4):352-362. DOI:10.1097/PSY.0000000000000689. |
[24] | SAMA J, VAIDYA D, MUKHERJEE M,et al. Effects of clinical depression on left ventricular dysfunction in patients with acute coronary syndrome[J]. J Thromb Thrombolysis,2021,51(3):693-700. DOI:10.1007/s11239-020-02268-4. |
[25] | SELIM A M, SARSWAT N, KELESIDIS I,et al. Plasma serotonin in heart failure:possible marker and potential treatment target[J]. Heart Lung Circ,2017,26(5):442-449. |
[26] | LIU M Y, ZHANG L J. Role of Ginkgo biloba extract in regulating 5-hydroxytrytamine and its receptor in heart failure mice[J]. Zhonghua Yi Xue Za Zhi,2018,98(25):2024-2029. |
[27] | 曹娟,刘习建,龚婷,等. 冠心病与抑郁症共病机制及治疗的研究进展[J]. 生命的化学,2019,39(5):993-997. DOI:10.13488/j.smhx.20190009. |
[28] | MAVRIDES N, NEMEROFF C B. Treatment of affective disorders in cardiac disease[J]. Dialogues Clin Neurosci,2015,17(2):127-140. DOI:10.31887/DCNS.2015.17.2/nmavrides. |
[29] | KIM Y K, NA K S, MYINT A M,et al. The role of pro-inflammatory cytokines in neuroinflammation,neurogenesis and the neuroendocrine system in major depression[J]. Prog Neuropsychopharmacol Biol Psychiatry,2016,64:277-284. |
[30] | BROWN L, KARMAKAR C, GRAY R,et al. Heart rate variability alterations in late life depression:a meta-analysis[J]. J Affect Disord,2018,235(1):456-466. DOI:10.1016/j.jad.2018.04.071. |
[31] | SESSA F, ANNA V, MESSINA G,et al. Heart rate variability as predictive factor for sudden cardiac death[J]. Aging:Albany NY,2018,10(2):166-177. DOI:10.18632/aging.101386. |
[32] | HARTMANN R, SCHMIDT F M, SANDER C,et al. Heart rate variability as indicator of clinical state in depression[J]. Front Psychiatry,2018,9(2):735-743. |
[33] | BORRIONE L, BRUNONI A R, SAMPAIO-JUNIOR B,et al. Associations between symptoms of depression and heart rate variability:an exploratory study[J]. Psychiatry Res,2018,262(4):482-487. DOI:10.1016/j.psychres.2017.09.028. |
[34] | KIRCANSKI K, WILLIAMS L M, GOTLIB I H. Heart rate variability as a biomarker of anxious depression response to antidepressant medication[J]. Depress Anxiety,2019,36(1):63-71. DOI:10.1002/da.22843. |
[35] | CHOI K W, JEON H J. Heart rate variability for the prediction of treatment response in major depressive disorder[J]. Front Psychiatry,2020,11:607. DOI:10.3389/fpsyt.2020.00607. |
[36] | KOCH C, WILHELM M, SALZMANN S,et al. A meta-analysis of heart rate variability in major depression[J]. Psychol Med,2019,49(12):1948-1957. |
[37] | SCHERF-CLAVEL M, WURST C, NITSCHKE F,et al. Extent of cortisol suppression at baseline predicts improvement in HPA axis function during antidepressant treatment[J]. Psychoneuroendocrinology,2020,114(4):104590-104598. |
[38] | DWYER J B, AFTAB A, RADHAKRISHNAN R,et al. Hormonal treatments for major depressive disorder:state of the art[J]. Am J Psychiatry,2020,177(8):686-705. DOI:10.1176/appi.ajp.2020.19080848. |
[39] | REINDL M, FEISTRITZER H J, REINSTADLER S J,et al. Thyroid-stimulating hormone and adverse left ventricular remodeling following ST-segment elevation myocardial infarction[J]. Eur Heart J Acute Cardiovasc Care,2019,8(8):717-726. |
[40] | FLORIANI C, GENCER B, COLLET T H,et al. Subclinical thyroid dysfunction and cardiovascular diseases:2016 update[J]. Eur Heart J,2018,39(7):503-507. |
[41] | LOH H H, LIM L L, YEE A,et al. Association between subclinical hypothyroidism and depression:an updated systematic review and meta-analysis[J]. BMC Psychiatry,2019,19(1):12-22. DOI:10.1186/s12888-018-2006-2. |
[42] | YANG G D, WANG Y, MA A Q,et al. Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction[J]. BMC Cardiovasc Disord,2019,19(1):83-94. |
[43] | WILDISEN L, MOUTZOURI E, BEGLINGER S,et al. Subclinical thyroid dysfunction and depressive symptoms:protocol for a systematic review and individual participant data meta-analysis of prospective cohort studies[J]. BMJ Open,2019,9(7):e029716. DOI:10.1136/bmjopen-2019-029716. |
[44] | FISCHER S, EHLERT U, AMIEL CASTRO R. Hormones of the hypothalamic-pituitary-gonadal (HPG) axis in male depressive disorders - a systematic review and meta-analysis[J]. Front Neuroendocrinol,2019,55(10):100792-100801. |
[45] | GRANDE D, TERLIZZESE P, GIOIA M I,et al. New frontiers in the therapeutic approach of patients with cardiovascular and endocrine diseases[J]. Endocr Metab Immune Disord Drug Targets,2019,19(5):605-621. |
[46] | ALEM M M. Endothelial dysfunction in chronic heart failure:assessment,findings,significance,and potential therapeutic targets[J]. Int J Mol Sci,2019,20(13):3198-3215. DOI:10.3390/ijms20133198. |
[47] | ZUCHI C, TRITTO I, CARLUCCIO E,et al. Role of endothelial dysfunction in heart failure[J]. Heart Fail Rev,2020,25(1):21-30. DOI:10.1007/s10741-019-09881-3. |
[48] | KOKRAS N, PAPADOPOULOU E, GEORGIOPOULOS G,et al. The effect of treatment response on endothelial function and arterial stiffness in depression. A prospective study[J]. J Affect Disord,2019,252(6):190-200. DOI:10.1016/j.jad.2019.04.024. |
[49] | GREANEY J L, SAUNDERS E F H, SANTHANAM L,et al. Oxidative stress contributes to microvascular endothelial dysfunction in men and women with major depressive disorder[J]. Circ Res,2019,124(4):564-574. DOI:10.1161/CIRCRESAHA.118.313764. |
[50] | HAN K M, CHOI S, KIM A,et al. The effects of 5-HTTLPR and BDNF Val66Met polymorphisms on neurostructural changes in major depressive disorder[J]. Psychiatry Res Neuroimaging,2018,273(3):25-34. DOI:10.1016/j.pscychresns.2018.01.005. |
[51] | OZ M D, BASKAK B, UCKUN Z,et al. Association between serotonin 2A receptor (HTR2A),serotonin transporter (SLC6A4) and brain-derived neurotrophic factor (BDNF) gene polymorphisms and citalopram/sertraline induced sexual dysfunction in MDD patients[J]. Pharmacogenomics J,2020,20(3):443-450. DOI:10.1038/s41397-019-0127-8. |
[52] | SOUSA A C, REIS R P D, PEREIRA A,et al. The genetic variant C825T of the beta 3 subunit of G protein is associated with hypertension in a Portuguese population[J]. Rev Port Cardiol (Engl Ed),2018,37(6):499-507. DOI:10.1016/j.repc.2017.09.018. |
[53] | NAM Y J, CHO C H, KIM L,et al. Association of G-protein β3 subunit C825T polymorphism with seasonal variations in mood and behavior[J]. Psychiatry Investig,2018,15(2):200-204. |
[54] | SONG E K, WU J R, MOSER D K,et al. Vitamin D supplements reduce depressive symptoms and cardiac events in heart failure patients with moderate to severe depressive symptoms[J]. Eur J Cardiovasc Nurs,2018,17(3):207-216. |
[55] | DJOUSSÉ L, COOK N R, KIM E,et al. Supplementation with vitamin D and Omega-3 fatty acids and incidence of heart failure hospitalization:VITAL-heart failure[J]. Circulation,2020,141(9):784-786. DOI:10.1161/CIRCULATIONAHA.119.044645. |
[56] | ZHAO Q, LI J F, YANG J,et al. Association of total cholesterol and HDL-C levels and outcome in coronary heart disease patients with heart failure[J]. Medicine (Baltimore),2017,96(9):e6094. DOI:10.1097/MD.0000000000006094. |
[57] | POPOVIC B, ZANNAD F, LOUIS H,et al. Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure[J]. Int J Cardiol,2019,274(1):195-201. |
[58] | GEISER F, MEIER C, WEGENER I,et al. Association between anxiety and factors of coagulation and fibrinolysis[J]. Psychother Psychosom,2008,77(6):377-383. |
[59] | DERELI S, KILINÇEL O, ÇERIK I B,et al. Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction[J]. Acta Cardiol,2020,75(8):774-782. DOI:10.1080/00015385.2020.1730577. |
[60] | CACCIATORE F, AMARELLI C, MAIELLO C,et al. Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure[J]. J Affect Disord,2020,272(4):132-137. DOI:10.1016/j.jad.2020.03.158. |
[61] | LI X L, ZHANG J, HUANG J,et al. A multicenter,randomized,double-blind,parallel-group,placebo-controlled study of the effects of qili Qiangxin capsules in patients with chronic heart failure[J]. J Am Coll Cardiol,2013,62(12):1065-1072. |
[62] | WANG X, HU D, DANG S,et al. Effects of traditional Chinese medicine shensong Yangxin capsules on heart rhythm and function in congestive heart failure patients with frequent ventricular premature complexes:a randomized,double-blind,multicenter clinical trial[J]. Chin Med J (Engl),2017,130(14):1639-1647. |
[63] | 刘岱岳,郭文勇,范鲁,等. 探讨人类肠道菌群调节剂联合抗抑郁药物治疗抑郁症的临床疗效[J]. 中国医学工程,2019,27(11):1-6. DOI:10.19338/j.issn.1672-2019.2019.11.001. |
[1] | 王旭, 魏戌, 朱立国, 冯天笑, 王志鹏, 师彬. 医工结合的中医手法治疗脊柱退行性疾病疗效机制研究:思路与前景[J]. 中国全科医学, 2023, 26(33): 4118-4124. |
[2] | 辛功恺, 丛欣, 袁磊, 程悦彤, 倪翠萍, 张巍巍, 張平平, 刘宇. 失智症老年人综合评估工具的研究进展[J]. 中国全科医学, 2023, 26(33): 4103-4109. |
[3] | 彰金, 丁治国, 祁烁, 李颖, 李伟强, 张媛媛, 周通. 血清甲状腺激素水平与心力衰竭患者住院期间预后的相关性研究[J]. 中国全科医学, 2023, 26(33): 4125-4129. |
[4] | 张思宇, 周郁秋, 杜晓慧, 王正君. 精神病未治期及其早期干预的研究进展[J]. 中国全科医学, 2023, 26(33): 4110-4117. |
[5] | 孟江涛, 杨思宇, 孙蕾, 雷瑞宁, 赵晓霞. 弥散张量成像联合运动诱发电位评估脑梗死偏瘫患者运动功能预后价值的研究进展[J]. 中国全科医学, 2023, 26(32): 4098-4102. |
[6] | 王佳欣, 赵亚利. 国内外医疗团队合作评估工具系统综述[J]. 中国全科医学, 2023, 26(31): 3951-3962. |
[7] | 苑喜微, 南月敏. 线粒体融合蛋白2的结构和功能及其在肝脏疾病中作用机制的研究进展[J]. 中国全科医学, 2023, 26(30): 3841-3846. |
[8] | 卫梦雨, 王佳佳, 张莹莹, 李春阳, 李建生. 阻塞性睡眠呼吸暂停患者报告结局测评工具研究现状分析[J]. 中国全科医学, 2023, 26(30): 3725-3733. |
[9] | 马艳艳, 任付先, 王宇, 高登峰. (中性粒细胞+单核细胞)/淋巴细胞比值对心力衰竭患者住院死亡的预测价值研究[J]. 中国全科医学, 2023, 26(30): 3791-3796. |
[10] | 肖雨倩, 白艳杰, 王岩, 陈淑颖, 陈丽敏, 孙可心, 万俊. 线粒体转移在脑卒中后认知障碍中的研究进展[J]. 中国全科医学, 2023, 26(30): 3833-3840. |
[11] | 何莉, 张逸凡, 沈雪纯, 孙燕, 赵洋. 中国大陆地区居民慢性病共病的流行趋势:一项Meta分析[J]. 中国全科医学, 2023, 26(29): 3599-3607. |
[12] | 潘晔, 刘志辉, 胡倩倩, 王留义. 中国老年人慢性病多病共存模式的研究[J]. 中国全科医学, 2023, 26(29): 3608-3615. |
[13] | 周思静, 罗邦安, 曹慧, 张熙, 王东欣. ≥65岁居民老年痴呆流行病学特征及其与慢性病共病的相关性研究[J]. 中国全科医学, 2023, 26(29): 3616-3621. |
[14] | 刘煜, 岳婷, 杨东宇, 赵中亭, 杨吉勃, 朱田田. 自噬在类风湿关节炎发病机制中的研究进展[J]. 中国全科医学, 2023, 26(29): 3710-3714. |
[15] | 张振东, 蔡斌, 王宏伟, 乔增勇. 肠道菌群及其代谢产物苯乙酰谷氨酰胺在慢性心力衰竭患者中的变化研究[J]. 中国全科医学, 2023, 26(29): 3665-3673. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||